Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAAR1 | Q96RJ0 | 3/20 | 0.31 |
| ▸ | NPC1 | O15118 | 1/20 | 0.30 |
| ▸ | GAA | P10253 | 1/20 | 0.30 |
| ▸ | RAB9A | P51151 | 1/20 | 0.30 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.30 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.30 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.30 |
| ▸ | ACHE | P22303 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2141121 | 0.88 | HDAC3 (0.35) | HDAC3HDAC1HDAC2 | |
| SCHEMBL463161 | 0.86 | KCNH2 (0.39) | HDAC3HDAC1HDAC2 | |
| SCHEMBL5764856 | 0.85 | KCNH2 (0.42) | ACHE | |
| SCHEMBL7447631 | 0.85 | KCNH2 (0.42) | ACHE | |
| SCHEMBL455820 | 0.83 | — | — | |
| SCHEMBL19405632 | 0.80 | DHODH (0.31) | — | |
| SCHEMBL27672098 | 0.77 | — | — | |
| SCHEMBL381275 | 0.77 | DAO (0.31) | — | |
| SCHEMBL258549 | 0.77 | TSHR (0.32) | TAAR1ACHE | |
| SCHEMBL8667928 | 0.76 | KDM4E (0.32) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6448259-B1 | CYCLOALKYL-4-OXONICOTINIC CARBOXAMIDES; AGONISTS, ANTAGONISTS OR INVERSE AGONISTS FOR GAMMA AMINOBUTYRIC ACID BINDING SITE, THE BENZODIAZEPINE RECEPTOR; ANXIETY, SLEEP AND SEIZURE DISORDERS SEDATIVE, ANXIOLYTIC AND ANTICONVULSANT ACTIVITY | NEUROGEN CORPORATION | 2002-09-10 | — | — | US | claimed |
| CN-107004906-B | Magnesium-containing electrolyte | 富士胶片和光纯药株式会社 | 2020-04-21 | — | — | CN | disclosed |
| US-10367231-B2 | Magnesium-containing electrolytic solution | FUJIFILM WAKO PURE CHEMICAL CORPORATION (JP) | 2019-07-30 | — | — | US | disclosed |
| EP-3226340-B1 | MAGNESIUM-CONTAINING ELECTROLYTIC SOLUTION | FUJIFILM WAKO PURE CHEMICAL CORP (JP) | 2018-11-07 | — | — | EP | disclosed |
| US-20170331154-A1 | MAGNESIUM-CONTAINING ELECTROLYTIC SOLUTION | WAKO PURE CHEMICAL INDUSTRIES, LTD. (JP) | 2017-11-16 | — | — | US | disclosed |
| EP-3226340-A1 | MAGNESIUM-CONTAINING ELECTROLYTIC SOLUTION | Wako Pure Chemical Industries, Ltd. (JP) | 2017-10-04 | — | — | EP | disclosed |
| EP-1416933-B8 | SUBSTITUTED PIPERIDINES AS MODULATORS OF THE MELANOCORTIN RECEPTOR | AMGEN INC (US) | 2008-08-27 | — | — | EP | disclosed |
| EP-1417190-A1 | SUBSTITUTED PIPERAZINES AS MODULATORS OF THE MELANOCORTIN RECEPTOR | Amgen Inc. (US) | 2004-05-12 | — | — | EP | disclosed |
| EP-1416933-A1 | SUBSTITUTED PIPERIDINES AS MODULATORS OF THE MELANOCORTIN RECEPTOR | Amgem, Inc. (US) | 2004-05-12 | — | — | EP | disclosed |
| WO-2003009850-A1 | SUBSTITUTED PIPERAZINES AS MODULATORS OF THE MELANOCORTIN RECEPTOR | AMGEN INC. (US) | 2003-02-06 | — | — | WO | disclosed |
| WO-2003009847-A1 | SUBSTITUTED PIPERIDINES AS MODULATORS OF THE MELANOCORTIN RECEPTOR | AMGEM, INC. (US) | 2003-02-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10367231-B2 | Magnesium-containing electrolytic solution | CA1, CA3, CA2 | TAAR1 2063/4885NPC1 4052/4885GAA 1680/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.